Chronic hepatitis B and hepatocarcinogenesis: does prevention of "collateral damage" bring the cure?
Manigold
Tobias
T
Liver Diseases Section, NIDDk, National Institutes of Health, DHHS, Bethesda, MD, USA.
Rehermann
Barbara
B
D000818:Animals; D000906:Antibodies / Q000494:pharmacology; D017209:Apoptosis; D006528:Carcinoma, Hepatocellular / Q000517:prevention & control* / Q000821:virology*; D002455:Cell Division; D053222:Fas Ligand Protein; D006514:Hepatitis B Surface Antigens / Q000235:genetics; D006515:Hepatitis B virus / Q000254:growth & development; D019694:Hepatitis B, Chronic; D007958:Leukocyte Count; D008099:Liver / Q000473:pathology / Q000821:virology; D008113:Liver Neoplasms / Q000517:prevention & control* / Q000821:virology*; D008114:Liver Neoplasms, Experimental / Q000517:prevention & control / Q000821:virology; D008562:Membrane Glycoproteins / Q000276:immunology / Q000502:physiology; D051379:Mice; D008822:Mice, Transgenic; D009504:Neutrophils; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology / Q000473:pathology; D019014:fas Receptor / Q000502:physiology
D000906:Antibodies; D053222:Fas Ligand Protein; C505658:Fasl protein, mouse; D006514:Hepatitis B Surface Antigens; D008562:Membrane Glycoproteins; D019014:fas Receptor